Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock. IMUX has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target […]
D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock. IMUX has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target […]
